PureTech Health (PRTC) Total Non-Current Liabilities (2019 - 2025)
PureTech Health (PRTC) reported Total Non-Current Liabilities of $182.7 million for Q4 2025, up 19.18% year-over-year from $153.3 million in Q4 2024, and up 27.21% on a QoQ basis from $143.6 million in Q2 2025.
PureTech Health (PRTC) has 7 years of Total Non-Current Liabilities data on file, last reported at $182.7 million in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 19.18% year-over-year to $182.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $182.7 million (up 19.18% YoY) and the FY2025 annual result came in at $182.7 million, up 19.18% from the prior year.
- Total Non-Current Liabilities grew to $182.7 million in Q4 2025 per PRTC's latest filing, from $143.6 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $182.7 million in Q4 2025 and bottomed at -$3.5 million in Q4 2023.
- The 5-year median for Total Non-Current Liabilities is $139.7 million (2021), against an average of $111.7 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities plunged 106.02%; it then jumped 4479.15% in 2024.
- Tracing PRTC's Total Non-Current Liabilities over 5 years: stood at $135.7 million in 2021, then tumbled by 57.14% to $58.2 million in 2022, then sank by 106.02% to -$3.5 million in 2023, then jumped by 4479.15% to $153.3 million in 2024, then rose by 19.18% to $182.7 million in 2025.
- Per Business Quant, the three latest PRTC Total Non-Current Liabilities figures stand at $182.7 million (Q4 2025), $143.6 million (Q2 2025), and $153.3 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 7.32 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 4.05 Bn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | 182.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 182.73 Mn |
| Jun 30, 2025 | 143.64 Mn |
| Dec 31, 2024 | 153.31 Mn |
| Dec 31, 2023 | -3.50 Mn |
| Dec 31, 2022 | 58.17 Mn |
| Dec 31, 2021 | 135.73 Mn |
| Dec 31, 2020 | 155.53 Mn |
| Dec 31, 2019 | 151.58 Mn |